You are here: Home » Companies » News
Business Standard

Pfizer could apply for emergency use of Covid-19 vaccine by late Nov

It would be the first time that Pfizer or any other leading Western vaccine developer provided such a specific timeline.

Pfizer | Coronavirus Vaccine | Coronavirus Tests

BS Web Team & Agencies  |  New Delhi 

test, coronavirus, covid

Inc expects to provide safety data and file for authorisation of the Covid-19 vaccine it is developing with German partner BioNTech in late November, assuming it receives positive efficacy and safety data from late-stage human trials, said the US company on Friday.

It would be the first time that or any other leading Western vaccine developer provided such a specific timeline, reported the Wall Street Journal. The drug giant said it continues to expect to have data on the vaccine’s effectiveness—whether it protects at least a majority of vaccinated people from the disease—later this month. It then expects to have data on the drug’s safety by the third week of November, said the Journal.

The timeline allows for possible US authorisation of a vaccine this year, a key step in controlling a pandemic that has killed more than a million and ravaged the global economy, said Reuters UK.

USA’s Food and Drug Administration has said it wants at least two months of safety data before authorizing emergency use of any experimental vaccine, according to the agency.

Pfizer’s Chief Executive Officer Albert Bourla noted in a letter posted on its website that the filing depended on several factors, including data on effectiveness that may or may not be available by late October.

Based on current trial enrollment and dosing pace, expects to have the safety data in the third week of November, Bourla said.

BioNTech and Pfizer previously set a target to produce up to 100 million vaccines globally by the end of this year. That initial batch would only be enough for 50 million people, though, because the vaccine, known as BNT162, consists of two shots, a so-called prime vaccination and a booster. The two haven’t disclosed how many doses they have already made, said the Journal.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 16 2020. 17:20 IST